Treatment of heart rhythm disorders by administration of 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds.

US5635511A · kind A · utility

Assignee

• Kali-Chemie Pharma GmbH · DE

Inventors

• Uwe Schoen · Burgdorf, DE
• Arman Farjam · Celle, DE
• Reinhard Brueckner · Hannover, DE
• Dieter Ziegler · Hemmingen, DE

Key dates

• Filing date: Jan 31, 1996
• Grant date: Jun 3, 1997
• Expiry date: Jan 31, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The use of 3,7,9,9-tetrasubstituted 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds for treating cardiac arrhytmias in larger mammals, including humans; novel antiarrhythmically active 3,7,9,9-tetrasubstituted compounds corresponding to the general formula Ia ##STR1## in which R.sup.1 is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms, PA1 R.sup.2 is lower alkyl, and PA1 R.sup.3 is lower alkyl, or PA1 R.sup.2 and R.sup.3 together form an alkylene chain having 3-6 carbon atoms, PA1 R.sup.4' is cyano, an R.sup.6 --O--CO-- group in which R.sup.6 is lower alkyl, an R.sup.7 --SO.sub.2 --NH-- group in which R.sup.7 is lower alkyl, or an R.sup.8 --CO--NH-- group in which R.sup.8 is lower alkyl or a phenyl group which is optionally substituted by halogen, cyano, nitro, or an R.sup.9 --SO.sub.2 -- radical in which R.sup.9 is lower alkyl, or an imidazolyl radical located in position 4 of the phenyl ring, and PA1 R.sup.5 is hydrogen or halogen, and physiologically acceptable acid addition salts thereof, and processes and intermediates for preparing them.